300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
LGBT
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Cannabis
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Celebrity
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database

Gegnum

VC Fund

São João Da Madeira, Portugal

Gegnum is a VC fund in São João Da Madeira focused on Medical and Life Science. Gegnum - Gestão e Investimentos, Lda. is a company based in São João da Madeira, Portugal.

Total investments:
1
Last investment:
Lead investor:
0%

Last updated:

Industries Gegnum invests in

MedicalLife ScienceBiotechnologyMedical DeviceHealth Diagnostics

Stages Gegnum invests in

Series A

Countries Gegnum invests in

Portugal

Investment Focus

Industry

  • Medical 1 (100%)
  • Life Science 1 (100%)
  • Biotechnology 1 (100%)
  • Medical Device 1 (100%)
  • Health Diagnostics 1 (100%)

Investments

CompanyDescriptionRoundLinks
Biomode is a startup venture based in Caldas das Taipas (Portugal) that aims to be a leading provider of rapid and accurate molecular diagnostic tests for identification of pathogens in the food, environment and life science industries.Biomode’s diagnostic kits are based on the PNA-FISH (Peptide Nucleic Acid Fluorescence In Situ Hybridisation)technology.Biomode’s founders are a group of researchers from the universities of Minho and Porto (Portugal) that is one of the few worldwide research groups with the skills to design PNA-FISH probes targeting specific pathogens.Biomode will enter the food industry diagnostics market with a kit for detecting Salmonella in food samples (Probe4Salmonella®) soon to be followed by two other kits for the detection of Listeria monocytogenes and E. coli O157:H7. On the clinical diagnostics area, Biomode has already developed a kit aimed at the rapid identification of clarithromycin resistance of H. Pylori strains (Probe4Pylori®) that is in the process of obtaining investigational device exemption from the Food and Drug Administration (FDA) in order to undergo field trials. $1.7M / Series A / Mar 19, 2015

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Payments
Retail
Film
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
LGBT
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Cannabis
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Celebrity
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Paraguay
Botswana
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Gegnum invest in?

Gegnum invests primarily in Medical, Life Science and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Portugal. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Gegnum last invest?

The most recent investment recorded for Gegnum closed in Mar 2015. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Gegnum Find emails